DocPharma raises $2M to build 100 licensed medicine dark stores

Bengaluru-based DocPharma has raised a $2 million pre-Series A led by Equentis and plans to expand its compliant prescription-medicine fulfilment network from 12+ to 50+ Indian cities through 100 licensed dark stores.

— Source publishedWed, 2 Sept, 2026, 10:19 IST·First seen Wed, 2 Sept, 2026, 10:22 IST·Source Entrackr

What happened

Bengaluru-based healthcare quick-commerce supply-chain startup DocPharma raised $2 million in a pre-Series A led by Equentis. It will build 100 licensed dark

Key facts

  • $2 million pre-Series A funding
  • 100 new compliant and licensed dark stores planned
  • expansion from 12+ to 50+ cities
  • serves 30+ health and wellness platforms
  • founded in 2023
  • 800,000+ orders fulfilled
  • 95%+ fulfilment rate
  • 500,000+ lives impacted
  • Plazza raised $15 million Series A
  • Plazza targets 15-30 minute medicine delivery

Why this matters

The expansion creates potential partnership or acquisition value for pharmacy, healthcare delivery, logistics, and quick-commerce players seeking licensed prescription fulfilment infrastructure.

What to watch

  • Number of licensed stores operational versus the 100-store target and pace of expansion beyond the initial 12+ locations.
  • New drug-controller guidance, state enforcement actions or court rulings affecting e-pharmacy, prescription delivery or dark-store licensing.
  • Reported delivery times, fill rates, prescription rejection rates and cold-chain compliance metrics.
  • Evidence of repeat-order growth in chronic therapies versus lower-margin acute medicine orders.
  • Partnership announcements with hospitals, diagnostic providers, insurers, pharmacy chains or last-mile logistics platforms.
  • Competitive responses from Tata 1mg, PharmEasy, Apollo 24/7, Netmeds and quick-commerce marketplaces.
  • Follow-on fundraising, which would signal whether the capital intensity of licensed network expansion is manageable.
  • Cluster launches around Bengaluru and other high-order-density cities before entering dispersed markets.
  • Secure state-level drug licenses, registered pharmacist capacity, cold-chain SOPs and auditable prescription-validation workflows.
  • Prioritize chronic-care categories, refill subscriptions and diagnostic/lab partnerships to increase repeat frequency and basket predictability.
  • Build B2B relationships with clinics, hospitals, insurers and employers to lower customer-acquisition costs.
  • Use the funding round to demonstrate city-level unit economics, likely positioning for a larger Series A tied to rollout milestones.
  • Differentiate from general quick-commerce platforms through guaranteed prescription compliance, medicine availability and consultation/refill support.

Also reported by